About EYLEA

EYLEA is a prescription medicine used to treat certain eye conditions, including neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and diabetic macular edema. It contains the active ingredient AFLIBERCEPT, which is a recombinant human fusion protein that acts as an inhibitor of vascular endothelial growth factor A (VEGF-A).

Key Benefits & Uses

Treatment of neovascular (wet) age-related macular degeneration to improve vision
Treatment of macular edema following retinal vein occlusion to reduce vision loss
Treatment of diabetic macular edema to improve vision in patients with diabetic retinopathy

Active Ingredient & Action

AFLIBERCEPT, the active ingredient in EYLEA, works by binding to and inhibiting vascular endothelial growth factor A (VEGF-A), which is involved in the formation of new blood vessels and the increase in permeability of existing blood vessels. By inhibiting VEGF-A, AFLIBERCEPT reduces the formation of new blood vessels and the leakage of fluid and protein from blood vessels, which can help to reduce vision loss and improve vision in patients with certain eye conditions.

Important Notes

It is essential to follow the dosage and administration instructions for EYLEA, as prescribed by a healthcare professional. Patients should also be aware of the potential risks and side effects associated with EYLEA, including eye pain, conjunctival hemorrhage, and increased intraocular pressure. Regular monitoring and follow-up appointments with a healthcare professional are necessary to ensure safe and effective treatment with EYLEA.